Bird flu vaccine made in powder form

Dec 26, 2007

A researcher in the Netherlands has created an avian flu vaccine in powder form.

The powdered form of the drug could prove to be a great weapon against avian flu since it can be stored and transported at room temperature. Current liquid vaccines need to be refrigerated, making it harder to transport into poor and developing countries, Radio Netherlands reported Tuesday.

Jean-Pierre Amorij of the University of Groningen, the man behind the idea, said a powder flu vaccine would be the only means of preventing many deaths in the case of a serious epidemic.

"The powder has particular advantages when it comes to transport and preservation because it can be kept at room temperature. The current flu vaccines are in liquid form, which means that you need refrigeration to transport and store them. This is an enormous problem in the developing countries," he said.

Copyright 2007 by United Press International

Explore further: Early bottlenecks in developing biopharmaceutical products delay commercialization

add to favorites email to friend print save as pdf

Related Stories

Food choices can affect antibiotic's effectiveness

Nov 19, 2010

When your child needs antibiotics, dietary choices can get complicated. Food can help support the body nutritionally and hinder the effectiveness of the medication, depending on what your child eats and when.

New research assesses use of Tamiflu, Relenza to prevent flu

Aug 03, 2009

Two common anti-influenza drugs — Relenza and Tamiflu — appear equally effective at preventing common flu symptoms when given before infection, say researchers from the Stanford University School of Medicine. However, ...

Major flu strain resistant to widely used antiviral drug

Jan 15, 2009

One of the major strains of the influenza virus this season has become resistant to Tamiflu - rendering the mainstay antiviral drug all but impotent and creating tough treatment options for patients who come down with the ...

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments : 0